News

The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the

The collaboration, under guidance by a joint committee of representatives from Sanofi Genzyme and the Johns Hopkins Multiple Sclerosis Center, will leverage certain technologies and methodologies designed to

This proof-of-concept study will evaluate the effect of N91115 as add-on therapy to Kalydeco™ (ivacaftor) in adult patients who have one copy of the F508del mutation and a

Last month, lawmakers failed to approve the US Government’s request for $1.9bn in emergency funding made in February. AHF said Congress is not concerned on the mosquito-borne and

The randomized, double-blind, standard of care-controlled trial, dubbed BLAST-AHF, assessed three doses of TRV027 plus standard heart failure therapy compared to placebo plus standard therapy in 618 patients

Pfizer will pay $99.25 in cash for each Anacor share. The transaction is scheduled to be completed in the third quarter of this year. Anacor is engaged in

The ongoing Phase 2b clinical trial evaluates efficacy on motor nerve conduction velocity, clinical outcomes, and visual acuity. "While there are many drugs available to patients and physicians

This approval was based on the impressive results of the registration study (Study 205), in which the once daily combination of 18 mg LENVIMA and 5 mg everolimus

Alprolix is the only recombinant factor IX Fc Fusion protein therapy for haemophilia B to offer people in the EU prolonged protection against bleeding episodes with fewer prophylactic